on Lyell Immunopharma Inc.
(NASDAQ: LYEL) stock is up on Monday as the company is providing an update on the safety profile of its LYL273 treatment in a Phase 1 clinical trial for relapsed or refractory metastatic colorectal cancer (mCRC).
New GI Prophylaxis Regimen Reduces Severe Side Effects As of May 5, 2026, data cutoff, 19 patients had been enrolled across the first two dose levels of the U.S. trial, which is evaluating LYL273 in patients with third-line or later metastatic colorectal cancer.
Ten patients received a newly implemented gastrointestinal prophylaxis regimen consisting of infliximab, vedolizumab, and budesonide, alongside a standardized safety management plan.
According to the company, the approach reduced the incidence of Grade greater than 2 diarrhea or colitis to 10% among patients receiving prophylaxis, compared with 55% in those who did not receive the regimen.
